Ventures
02 — Investment

Where the science is ready to be tested in patients.

We are focusing on the following investment opportunities.

Criteria matrix

Sectors

  • Drug Discovery (First-in-class or new biology-based approach)

  • Innovative Platform Technologies for Drug Discovery

  • Spin-out Opportunities from Taiho Pipelines

  • Medical Device / Diagnostics / Digital Healthopportunistic

Therapeutic areas

  • Oncology

  • "Non-oncology" (Immunology / Allergy / Bone / Muscle / Orphan)

Modality

  • Small Molecules

  • Biologics

  • Gene / Cell Therapy

Stage

  • Research to Pre-IND

  • IND to PoCopportunistic

Mandate

We invest where the science is ready to be tested in patients.

Pre-IND through proof of concept. Oncology, immunology, urology. First-in-class molecules or new biology — not "me-too" programs targeting the same receptor with a different linker.

We syndicate, we operate, and where the asset earns it we underwrite a build-to-buy or option-type structure with our corporate parent. The legacy /investment-criteria page names this explicitly: company creation, spinouts, and option-type investments alongside pure equity.

See what these criteria have selected.

Open the portfolio